PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2014.3142016481208-215p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal CancerSe Hyun Kim, Kyu Hyun Park, Sang Joon Shin, Kang Young Lee, Tae Il Kim, Nam Kyu Kim, Sun Young Rha, Jae Kyung Roh, Joong Bae Ahnhttp://e-crt.org/upload/pdf/crt-2014-314.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2014.314, http://www.e-crt.org/upload/pdf/crt-2014-314.pdf
Annals of Oncology10.1016/s0923-7534(20)33151-3201223ix185P16(INK4A) Gene Hypermethylation and Kras Mutation are Independent Predictors of FolFiri and Cetuximab Chemotherapy in Patients with Metastatic Colorectal Cancer (MCRC)S.H. Kim, K.H. Park, S.J. Shin, K.Y. Lee, T.I. Kim, N.K. Kim, S.Y. Rha, J.K. Roh, J.B. Ahnhttps://api.elsevier.com/content/article/PII:S0923753420331513?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420331513?httpAccept=text/plain
Annals of Oncology10.1016/s0923-7534(20)33171-9201223ix191-ix192Quality of Life Analysis in Patients with Kras Wild-Type Metastatic Colorectal Cancer Treated with First-Line Folfiri Plus CetuximabI. Láng, C. Köhne, G. Folprecht, P. Rougier, D. Curran, E. Hitre, U. Sartorius, I. Griebsch, E. Van Cutsemhttps://api.elsevier.com/content/article/PII:S0923753420331719?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420331719?httpAccept=text/plain
Community Oncology10.1016/j.cmonc.2012.09.0062012910304-306Cetuximab plus FOLFIRI in first-line treatment of KRAS mutation-negative, EGFR-positive metastatic colorectal cancerJame Abrahamhttps://api.elsevier.com/content/article/PII:S1548531512005712?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1548531512005712?httpAccept=text/plain
European Journal of Cancer Supplements10.1016/s1359-6349(09)71173-52009723456078 Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trialI. Lang, C.H. Köhne, G. Folprecht, M.P. Nowacki, S. Cascinu, I. Shchepotin, J. Maurel, D. Cunningham, A. Zubel, E. Van Cutsemhttps://api.elsevier.com/content/article/PII:S1359634909711735?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1359634909711735?httpAccept=text/plain
Medical Oncology10.1007/s12032-014-0935-22014315Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese populationYe Chen, Dan Cao, Feng Bi, Qiu Li, Meng Qiuhttp://link.springer.com/content/pdf/10.1007/s12032-014-0935-2.pdf, http://link.springer.com/article/10.1007/s12032-014-0935-2/fulltext.html, http://link.springer.com/content/pdf/10.1007/s12032-014-0935-2
Annals of Oncology10.1093/annonc/mdw523.024201627vii99Retrospective Study as FirstLine Chemotherapy cetuximab plus FOLFIRI for unresectable KRAS wild type colorectal cancerNorio Ureshino, Shinsuke Ogusuhttps://api.elsevier.com/content/article/PII:S0923753419539333?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419539333?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/27/suppl_7/mdw523.024/22971730/mdw523.024.pdf
Chemotherapy10.1159/000440693201561151-56Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal CancerPayam Azadeh, Nafiseh Mortazavi, Arezoo Tahmasebi, Farnaz Hosseini Kamal, Kambiz Novinhttps://www.karger.com/Article/Pdf/440693, https://www.karger.com/Article/Pdf/440693, https://www.karger.com/Article/Pdf/440693
Annals of Oncology10.1093/annonc/mds332201223102771-2772Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306F. Pietrantonio, M.C. Garassino, V. Torri, F. de Braudhttps://api.elsevier.com/content/article/PII:S0923753419379815?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419379815?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/23/10/2771/489038/mds332.pdf
Yearbook of Surgery10.1016/j.ysur.2011.04.08820122012322-323Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabT.J. Eberleinhttps://api.elsevier.com/content/article/PII:S0090367111001534?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0090367111001534?httpAccept=text/plain